AEterna’s missed Phase 3 gets ho-hum analyst reaction
December 7, 2009 by leonardzehr · Leave a Comment
Analysts are not surprised that Aeterna Zentaris’ cetrorelix drug candidate missed its primary endpoint in a Phase 3 clinical trial in Europe, matching the disappointing outcome of a similar pivotal trial in the U.S. earlier this year. RBC Capital Markets now expects AEterna (NASDAQ:AEZS; TSX:AEZ) to terminate the cetrorelix program and focus on its other [...]
Listen to BioTuesdays 
